

Major shareholder transaction

Notification pursuant to Section 28a of the Danish Securities Trading Act

Copenhagen and Oslo, 3rd September 2012

Affitech has today received a major shareholder notification from Trans Nova Investments Ltd., who in accordance with Section 28a of the Danish Securities Trading Act, notifies, on behalf of Alexander Shuster, Chairman of the Board of Directors of Affitech A/S, of the following transactions:

Name	Trans Nova Investments Limited
Reason for reporting	Related party to Alexander Shuster, Chairman of the Board of Affitech A/S
Issuer and ISIN	Affitech A/S/DK0015966592
Type of transaction	Purchase of shares
Date of transaction	31 st August, 2012
Relevant market	NASDAQ OMX COPENHAGEN A/S
Number of traded securities and market value	25,075,235 shares. Market value DKK 5,015,047
Number of traded securities and market value	408,853 shares. Market value DKK 75,760.46

Contact

Randi Krogsgaard, Director IR & Communications

Tel # +45 2320 1001, e-mail: ir@affitech.com

About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.